ES2732252T3 - Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante - Google Patents

Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante Download PDF

Info

Publication number
ES2732252T3
ES2732252T3 ES13721452T ES13721452T ES2732252T3 ES 2732252 T3 ES2732252 T3 ES 2732252T3 ES 13721452 T ES13721452 T ES 13721452T ES 13721452 T ES13721452 T ES 13721452T ES 2732252 T3 ES2732252 T3 ES 2732252T3
Authority
ES
Spain
Prior art keywords
seq
smad7
antisense oligonucleotide
diabetes
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13721452T
Other languages
English (en)
Spanish (es)
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
University of Miami
Original Assignee
Nogra Pharma Ltd
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, University of Miami filed Critical Nogra Pharma Ltd
Application granted granted Critical
Publication of ES2732252T3 publication Critical patent/ES2732252T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13721452T 2012-04-18 2013-04-18 Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante Active ES2732252T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
ES2732252T3 true ES2732252T3 (es) 2019-11-21

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13721452T Active ES2732252T3 (es) 2012-04-18 2013-04-18 Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante

Country Status (14)

Country Link
US (3) US10081809B2 (enExample)
EP (1) EP2839004B1 (enExample)
JP (2) JP6348484B2 (enExample)
KR (1) KR20150003824A (enExample)
CN (2) CN104487574B (enExample)
AU (1) AU2013249191B2 (enExample)
CA (1) CA2870547A1 (enExample)
DK (1) DK2839004T3 (enExample)
ES (1) ES2732252T3 (enExample)
IN (1) IN2014DN08158A (enExample)
MX (1) MX370149B (enExample)
NZ (1) NZ630914A (enExample)
RU (1) RU2667960C2 (enExample)
WO (1) WO2013158868A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2739302C2 (ru) 2008-11-13 2020-12-22 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2704092T3 (es) * 2014-04-30 2019-03-14 Procter & Gamble Composición limpiadora
EP3140658A2 (en) 2014-05-09 2017-03-15 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
CN112840025A (zh) * 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU2002363182A1 (en) 2001-11-02 2003-05-12 Ribopharma Ag Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2761262T3 (es) * 2003-06-13 2020-05-19 Alnylam Europe Ag Acido ribonucleico bicatenario con elevada eficacia en un organismo
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
WO2006035434A2 (en) 2004-09-28 2006-04-06 Quark Biotech, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
PL2281042T3 (pl) 2008-04-18 2016-01-29 Baxter Int Kompozycja na bazie mikrosfer do zapobiegania i/lub cofania nowego przypadku cukrzycy autoimmunologicznej
RU2739302C2 (ru) 2008-11-13 2020-12-22 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
NZ630914A (en) 2012-04-18 2017-01-27 Nogra Pharma Ltd Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
MX363746B (es) 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
EP3140658A2 (en) 2014-05-09 2017-03-15 Nogra Pharma Limited Methods for treating inflammatory bowel disease
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
EP3562943A1 (en) 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
KR20150003824A (ko) 2015-01-09
CN104487574B (zh) 2017-07-07
RU2667960C2 (ru) 2018-09-25
HK1207117A1 (en) 2016-01-22
US20200239884A1 (en) 2020-07-30
US10081809B2 (en) 2018-09-25
RU2014146170A (ru) 2016-06-10
JP2015514778A (ja) 2015-05-21
JP6348484B2 (ja) 2018-06-27
DK2839004T3 (da) 2019-07-01
NZ630914A (en) 2017-01-27
WO2013158868A1 (en) 2013-10-24
CN104487574A (zh) 2015-04-01
CA2870547A1 (en) 2013-10-24
AU2013249191B2 (en) 2019-01-03
IN2014DN08158A (enExample) 2015-05-01
AU2013249191A1 (en) 2014-10-09
MX2014012650A (es) 2015-04-08
CN107252492A (zh) 2017-10-17
MX370149B (es) 2019-12-03
US20190136237A1 (en) 2019-05-09
JP2018131468A (ja) 2018-08-23
US20150315573A1 (en) 2015-11-05
EP2839004B1 (en) 2019-06-12
US10443056B2 (en) 2019-10-15
EP2839004A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2732252T3 (es) Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
KR101800333B1 (ko) 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
AU2018211325B2 (en) Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
KR20220061248A (ko) 안과적 질환을 치료하거나 예방하기 위한 방법
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
AU2024205206A1 (en) Method for managing pain
KR20170122769A (ko) 지방이상증 집단에서 아포지단백질 C-III (ApoCIII) 발현의 조절
US20210290595A1 (en) Gfi1 inhibitors for the treatment of hyperglycemia
HK1207117B (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation